Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 93 of the 100 references it cites were found in a registry or an index; 60 of the 81 sources its claims cite were checked for support.
Abstract
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D/+; Trp53LSL-R172H/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018.
Overview
CoChat Summary
TL;DR
This multimodal study defines heterogeneous genetic and non-genetic resistance mechanisms to mutant-selective KRAS inhibition in pancreatic ductal adenocarcinoma (PDAC), using patient ctDNA and preclinical models. It finds recurrent RTK–RAS/PI3K pathway alterations, cell-cycle/efflux amplifications, and a drug-resistant partial EMT cell state, supporting combination strategies with chemotherapy or RTK/CLDN18.2-directed agents.
Key findings
- In 22 patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, 18/22 (81%) had PR/SD and acquired resistance, 4/22 had primary resistance, and putative genetic resistance mechanisms were identified in 9/22 (41%); across an aggregate KRASG12C cohort, genetic mechanisms were found in 51% of NSCLC, 52% of CRC, 46% of PDAC, and 75% of other GI cancers, while no putative genetic mechanism was identified in 54% of PDAC, 49% of NSCLC, and 48% of CRC.
- In preclinical models, MRTX1133 selectively inhibited KRASG12D-mutant cells across 877 PRISM cell lines; among 46 KRASG12D lines, 22 were sensitive and 24 resistant by AUC, with resistance associated with EMT, RTK–RAS pathway gene copy gains, PI3K–AKT–mTOR activation, and MYC/cell-cycle signatures.
- In the autochthonous KPC GEMM, MRTX1133 prolonged median survival to 10.7 weeks versus 1 week for vehicle (P = 2.08e–6), with complete responses in 67% (10/15), PRs in 27% (4/15), and primary resistance in 1/15; 55% (6/11) of endpoint MRTX1133-resistant tumors had high-level amplifications including Myc, Kras, Yap1, and Cdk6/Abcb1a/b.
- Single-nucleus RNA-seq of 68,479 nuclei showed MRTX1133-resistant tumors shifted toward pEMT (60% of nuclei) and mesenchymal (30%) states, and combination MRTX1133 plus gemcitabine/n(ab)-paclitaxel prevented relapse in orthotopic and metastatic models, with no lung metastases in combination-treated mice in the established-metastasis assay.
Methods
- Patient ctDNA from pretreatment and end-of-therapy plasma was sequenced from patients with KRASG12C-mutant PDAC treated on KRYSTAL-1 (adagrasib) or CodeBreaK100 (sotorasib), plus additional GI cancer samples and previously published KRASG12C inhibitor resistance cohorts.
- Preclinical profiling included PRISM multiplex cell-line screening (877 lines), KRASG12D-mutant PDAC patient-derived organoids (n = 20), isogenic MRTX1133-resistant cell lines, KPC GEMMs, PDX models, WES, bulk RNA-seq, snRNA-seq, RPPA, RTK arrays, immunoblots, IHC, and multiplex immunofluorescence.
- Analyses included AUC/dose-response modeling, GSEA, NMF metaprogram identification, inferCNV, pySCENIC regulon analysis, Markov absorption-based cell-state classification, and survival/statistical comparisons as described.
Limitations
- Stated: human PDAC resistance analysis relied primarily on ctDNA, and the authors note that future biopsies from patients progressing on RAS inhibitors are needed to fully interrogate genetic and non-genetic resistance.
- Stated: preclinical studies focused on the KRASG12D inhibitor MRTX1133; resistance mechanisms need evaluation with pan-RAS/pan-KRAS inhibitors and drugs of different selectivity/mechanism to define cross-resistance patterns.
- Evident from the text: the patient cohort is described as rare and limited to 22 PDAC patients, ctDNA-based detection may miss resistance drivers, and some resistant tumors/subclones lacked identifiable genomic drivers, leaving non-genetic mechanisms incompletely resolved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
28 Valid · 0 Not valid · 6 Not checked · 168 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additional investigations of combination therapy strategies with MRTX1133 in preclinical models of PDAC have suggested that co-targeting of EGFR may have enhanced efficacy over monotherapy (30, 34).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Supportedcites [30] Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD,. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 2022; 28: 2171– 82. 36216931 source
In the section on cetuximab combinations, the paper reports that cetuximab, an EGFR-targeting antibody, improved the anti-tumor efficacy of MRTX1133 over either agent alone in all seven pancreatic or colon xenograft models evaluated. It also reports stronger pathway inhibition in the AsPC-1 pancreatic cancer model, supporting the claim's qualified statement about preclinical PDAC models. (LLM, conf=0.94)
- Supportedcites [34] Gulay KCM, Zhang X, Pantazopoulou V, Patel J, Esparza E, Pran Babu DS,. Dual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res 2023; 83: 3001– 12. 37378556 PMC10502451 source
The “Irreversible pan-ERBB inhibitors synergize with MRTX1133 in vitro” section reports synergy in PDAC models with EGFR-targeting agents, although it was less consistent than with pan-ERBB inhibition. The “KRAS G12D-mutant PDAC cells” section reports greater tumor-growth inhibition with MRTX1133 plus afatinib than with MRTX1133 alone in transplant models. Together, these findings support the hedged claim of enhanced efficacy, with the qualification that the strongest evidence is for pan-ERBB rather than EGFR-only inhibition. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although these early clinical trial results need to be confirmed in larger studies, the efficacy of sotorasib and adagrasib in advanced, chemotherapy-treated disease compares favorably to historical data on second-line chemotherapy efficacy in PDAC, where response rates are consistently less than 10% and median PFS is less than 3 months (28, 29).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Not checked — no full text of the sourcecites [28] Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA,. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019; 108: 78– 87. 30654298 source
- Partly supportedcites [29] Huffman BM, Basu Mallick A, Horick NK, Wang-Gillam A, Hosein PJ, Morse MA,. Effect of a MUC5AC antibody (NPC-1C) administered with second-line gemcitabine and nab-paclitaxel on the survival of patients with advanced pancreatic ductal adenocarcinoma: a randomized clinical trial. JAMA Netw Open 2023; 6: e2249720. 36602796 PMC9856813 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates an associationn = 38- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent preclinical work with MRTX1133 has demonstrated excellent responses in cell line and xenograft models of PDAC (30, 32).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Introduction
What the sources say
- Supportedcites [30] Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD,. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med 2022; 28: 2171– 82. 36216931 source
The section on KRASG12D-mutant cancer cell lines reports potent inhibition of cell viability by MRTX1133. The xenograft-results section reports at least 30% tumor regression in 8 of 11 pancreatic cancer models. Our copy provides no page numbers for these passages. (LLM, conf=0.92)
- Supportedcites [32] Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B,. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell 2023; 41: 1606– 20.e8. 37625401 PMC10785700 source
The section ‘KRAS* inhibition suppresses the growth of human PDAC cells’ (page not available) reports that MRTX1133 inhibited proliferation in KRAS G12D-mutant PDAC cell lines. It also reports significantly reduced tumor weights in orthotopic xenografts and tumor control or slight regression in all eight patient-derived xenografts. (LLM, conf=0.91)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
What the sources say
- Supportedcites [44] Raghavan S, Winter PS, Navia AW, Williams HL, DenAdel A, Lowder KE,. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Cell 2021; 184: 6119– 37.e26. 34890551 PMC8822455 source
The Results section, “State-specific TME signals drive transcriptional heterogeneity and drug response” (page unavailable), reports clinical trial data in which patients with basal phenotypes tended to have poorer outcomes with combination chemotherapy. It also reports that organoids in a basal state were less sensitive to several chemotherapies than when they returned to a classical state. Together, these support the claim’s cautious comparison. (LLM, conf=0.91)
- Supportedcites [58] Aung KL, Fischer SE, Denroche RE, Jang G-H, Dodd A, Creighton S,. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res 2018; 24: 1344– 54. 29288237 PMC5968824 source
The Results report more partial responses to first-line chemotherapy in classical than basal-like tumors (13/38 versus 1/12). The Discussion explicitly states that patients with advanced classical PDAC responded better than those with basal-like PDAC; the Results also report shorter survival for the basal-like subtype. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Supportedcites [59] O’Kane GM, Grünwald BT, Jang G-H, Masoomian M, Picardo S, Grant RC,. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Cancer Res 2020; 26: 4901– 10. 32156747 source
The ‘Response to chemotherapy according to modified Moffitt classification’ section reports a higher overall response rate in classical than basal-like PDAC (33% versus 10%, p=0.02). The ‘Overall survival’ section reports shorter survival for the basal-like subgroup receiving mFFX and identifies subtype as prognostic; it found no survival difference between subgroups receiving GnP, so the claim is appropriately framed as a suggestion rather than a benefit with every regimen. (LLM, conf=0.92)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Finally, we identified a novel partial EMT (pEMT) signature analogous to previously described hybrid states along the epithelial–mesenchymal axis (Supplementary Fig. S8A; refs. 50, 53).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Malignant Cell State Evolution in Response and Resistance to KRASG12D Inhibition
What the sources say
- Not checked — no full text of the sourcecites [50] Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R,. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature 2023: 618; 598– 606. 37258682 source
- Supportedcites [53] Barkley D, Moncada R, Pour M, Liberman DA, Dryg I, Werba G,. Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet 2022; 54: 1192– 201. 35931863 PMC9886402 source
The Results describe a partial mesenchymal (pEMT) module distinct from a complete mesenchymal module and note that pEMT had previously been characterized in other cancer types. This supports the citation’s comparison to previously described partial EMT states; the citing authors’ identification of a novel signature is their own finding, not a finding attributed to this source. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
104 more claims · 7 with their cited sources checked
Create a free account to see all 202 claims and to verify the 2 references still open.
- It may state two separate claims as one. 68
- Probably not a substantial claim. 32
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the established role of lineage plasticity in resistance to KRAS-targeted therapies,26–31 effective therapeutic interventions targeting drivers of lineage plasticity remain lacking.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Differentiation into alveolar type 1 (AT1)-like,26 squamous,27,28 as well as mucinous states29 has been implicated to contribute to KRAS inhibitor tolerance in lung adenocarcinoma, whereas transition into a classical state is observed in PDAC cells surviving KRAS-targeted therapy.30,31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lineage plasticity has emerged as a critical mechanism of non-genetic resistance to KRAS-targeted therapies in NSCLC and PDAC.27–31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In NSCLC, KRAS-mutant tumors evade therapy through transition into AT1-like,29 squamous,27,28 or mucinous states,29 while pancreatic cancer cells adopt a classical epithelial state to bypass KRAS inhibition.30,31”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic alterations, especially secondary RAS mutations, have been identified as one of the most common mechanisms of acquired resistance to KRAS inhibitors in patients [49, 51–55].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [55]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Methods > In Vivo Protocols
“100% to 76% = 4”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Methods > In Vivo Protocols
“51% to 76% = 3”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
“In vivo, 6649C2-LM implanted subcutaneously grows slightly more rapidly than the parental cell line, showing overall more aggressive growth and faster outgrowth under MRTX1133 treatment (Fig. 6D).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Efficacy of Combination Chemotherapy with KRASG12D Inhibition in PDAC
“We previously generated a transplantable cell line model of metastatic PDAC (6694C2-LM) by isolating and culturing a tumor nodule from a spontaneous lung metastasis of a 6649C2 tumor-bearing mouse (60).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Genetic Mechanisms of Resistance to KRASG12C Inhibition in Patients with PDAC
“C, Co-mutation plot displaying pathogenic and likely pathogenic treatment-emergent variants and genomic amplification of putative drivers of resistance detected in ctDNA samples from PDAC patients with acquired resistance to adagrasib (patients 1–8) or sotorasib (patients 9–22).”
§ Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer > Results > Genetic Mechanisms of Resistance to KRASG12C Inhibition in Patients with PDAC
“Primary resistance with PD was observed in 4/22 patients (patients 1, 9, 10, 11).”
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“79 ; version 1.38.3) log-normalized tumor-derived expression profiles.”
InfluentialFiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890 · cited 1×
“Finally, individual dot densitometry analysis was conducted using Fiji image analysis software (83). snRNA-seq Sample Preparation, Library Generation, and Sequencing.”
MethodNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“…was determined based on routine clinical evaluation by a blinded, board-certified radiologist and defined as SD for at least 12 weeks or a partial or complete response followed by disease progression based on Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 for CT imaging (75).”
MethodInfluentialSiegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · cited 1×
“After evaluating features of response and resistance to MRTX1133 in vitro , we sought to investigate the efficacy of KRAS G12D inhibition in the immunocompetent, autochtho-nous KPC ( Kras LSL-G12D/ + ; Trp53 LSL-R172H/ + ; p48-Cre ) genetically engineered mouse model (GEMM) of PDAC (49).”
BackgroundHidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 2×
“…published cases of lung neuroendocrine tumor (patient 105; 14), melanoma, small cell lung cancer and spindle cell carcinoma (patients 10, 21 and 8; 19) to create a pan-cancer cohort of 132 patients with KRAS G12C mutation and displaying acquired resistance to adagrasib, sotorasib, or…”
BackgroundData-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303 · cited 1×
“54).”
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 3×
“Primary resistance with PD was observed in 4/22 patients (patients 1, 9, 10, 11).”
BackgroundSelf-citationMoffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194 · cited 1×
“We additionally used a panel of PDAC transcriptional subtype signatures as well as multiple curated gene sets from the previously published work (44, 50, 52, 53, 88–91).”
MethodOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · cited 1×
“48).”
Self-citationSubtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Self-citationKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Self-citationHallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · cited 3×
“Primary resistance with PD was observed in 4/22 patients (patients 1, 9, 10, 11).”
BackgroundSelf-citationOncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · cited 4×
“Notably, some of these features have been previously linked to resistance to KRAS suppression (5).”
BackgroundInfluentialSelf-citationAcquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
False discovery rates: a new deal
Stephens, M. (2016) · Biostatistics · doi:10.1093/biostatistics/kxw041 · Cited by 1,067
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1×
“Consistent with prior work showing that oncogenic KRAS drives production of GM-CSF and recruitment of granulocytes (61, 62), we found that MRTX1133 treatment resulted in reduced immuno-suppressive growth factors and reduced infiltration of granulocytic and monocytic myeloid-derived suppressor cells…”
Self-citationDiscovering the anticancer potential of non-oncology drugs by systematic viability profiling
Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0018-6 · Cited by 878 · cited 2×
“This formulation puts AUC values on a scale between 0 and 1, where lower AUC values indicate increased sensitivity to treatment (43).”
BackgroundSelf-citationSingh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Ianevski, A., Giri, A. K., & Aittokallio, T. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac382 · Cited by 778
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770 · cited 1×
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
BackgroundIdentification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01688 · Cited by 769 · cited 2×
“KRAS G12D mutations occur in nearly 40% of PDAC (25) and the recent development of selective inhibitors of the KRAS G12D mutant protein may have substantial clinical impact on the treatment of patients with PDAC (30, 31).”
BackgroundMethodSelf-citationLi, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750
Self-citationKRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744 · cited 1×
“…of KRAS via RNA interference or genetically engineered inducible Kras G12D alleles (i.e., “ iKras ” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRAS G12D suppression (35–38).”
BackgroundOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 1×
“Consistent with prior work showing that oncogenic KRAS drives production of GM-CSF and recruitment of granulocytes (61, 62), we found that MRTX1133 treatment resulted in reduced immuno-suppressive growth factors and reduced infiltration of granulocytic and monocytic myeloid-derived suppressor cells…”
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
Self-citationShah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02465-7 · Cited by 681
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Chan-Seng-Yue, M., Kim, J. C., Wilson, G. W., Ng, K., Figueroa, E. F., O’Kane, G. M., Connor, A. A., Denroche, R. E., Grant, R. C., McLeod, J., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0566-9 · Cited by 669 · cited 1×
“Human patient-derived xenograft (PDX) models have been shown to faithfully recapitulate human PDAC subtype diversity, including both classical and basal-like subtypes (56), with the basal-like PDAC phenotype showing phenotypic similarities with the mesenchymal cell state in PDAC (57).”
Backgroundde Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618 · cited 1×
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
BackgroundClaudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., Zhang, M., Peng, Z., Zhou, J., Cao, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01800-8 · Cited by 604 · cited 1×
“2-targeting therapies have demonstrated efficacy in clinical trials for GI cancers, including antibodies, antibody-drug conjugates (ADC), and CAR-T cells (64–66).”
BackgroundSelf-citationMicroenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Raghavan, S., Winter, P. S., Navia, A. W., Williams, H. L., DenAdel, A., Lowder, K. E., Galvez-Reyes, J., Kalekar, R. L., Mulugeta, N., Kapner, K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.017 · Cited by 592 · cited 6×
“Genetic profiling was performed on the patient’s tissue biopsies using WGS or a targeted sequencing panel (OncoPanel), as previously described (44, 80).”
BackgroundMethodInfluentialSelf-citationProfiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx
Steen, C. B., Liu, C. L., Alizadeh, A. A., & Newman, A. M. (2020) · Methods in Molecular Biology · doi:10.1007/978-1-0716-0301-7_7 · Cited by 566 · cited 1×
“A signature matrix generated with expression profiles from normal plasma evRNA and TCGA PDAC tumor samples was utilized to deconvolve the PDAC evRNA, enabling the generation of non-tumor and tumor-derived gene expression profiles by CIBERSORTx (77) and CODEFACS (78).”
MethodHallmarks of transcriptional intratumour heterogeneity across a thousand tumours
Gavish, A., Tyler, M., Greenwald, A. C., Hoefflin, R., Simkin, D., Tschernichovsky, R., Galili Darnell, N., Somech, E., Barbolin, C., Antman, T., et al. (2023) · Nature · doi:10.1038/s41586-023-06130-4 · Cited by 556 · cited 4×
“The pEMT metaprogram observed at resistance to KRAS inhibition also resembles similar signatures described in recent cell state atlases of human tumors, suggesting that cells expressing features of this state may be present at baseline, before treatment with a KRAS inhibitor (50, 53).”
MethodResultInfluentialAnti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Self-citationRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543 · cited 2×
“…alterations at the time of acquired resistance were observed in several patients, including amplifications/gains of KRAS G12C (patients 6, 9, 13, 22), amplification/ gain of EGFR (patients 2, 13), activating PIK3CA mutations (patients 13, 22), and an oncogenic NFE2L2 D29H variant (patient 21; Fig.”
BackgroundPan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth
Kim, D., Herdeis, L., Rudolph, D., Zhao, Y., Böttcher, J., Vides, A., Ayala-Santos, C. I., Pourfarjam, Y., Cuevas-Navarro, A., Xue, J. Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06123-3 · Cited by 534 · cited 1×
“Recently developed “pan-RAS” or “pan-KRAS” inhibitors capable of targeting all RAS isoforms or all KRAS alleles will be broadly applicable to most patients with PDAC (71–74).”
BackgroundBarkley, D., Moncada, R., Pour, M., Liberman, D. A., Dryg, I., Werba, G., Wang, W., Baron, M., Rao, A., Xia, B., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01141-9 · Cited by 532 · cited 3×
“The pEMT metaprogram observed at resistance to KRAS inhibition also resembles similar signatures described in recent cell state atlases of human tumors, suggesting that cells expressing features of this state may be present at baseline, before treatment with a KRAS inhibitor (50, 53).”
MethodResultTanaka, N., Lin, J. J., Li, C., Ryan, M. B., Zhang, J., Kiedrowski, L. A., Michel, A. G., Syed, M. U., Fella, K. A., Sakhi, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0365 · Cited by 527 · cited 1×
“At the genomic level, we did not observe putative drug-binding site mutations in Kras , such as those that have previously been noted to cause resistance to KRAS inhibition in human tumors (14, 18, 20).”
BackgroundSotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2208470 · Cited by 527 · cited 1×
“In these patients, a 21% objective response rate (ORR), a median progression-free survival (PFS) of 4.0 months, and a median overall survival (OS) of 6.9 months were observed (26).”
BackgroundInfluentialSelf-citationGarcia, E. P., Minkovsky, A., Jia, Y., Ducar, M. D., Shivdasani, P., Gong, X., Ligon, A. H., Sholl, L. M., Kuo, F. C., MacConaill, L. E., et al. (2017) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2016-0527-oa · Cited by 524 · cited 1×
“Genetic profiling was performed on the patient’s tissue biopsies using WGS or a targeted sequencing panel (OncoPanel), as previously described (44, 80).”
MethodEGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504 · cited 1×
“Recent work has also highlighted the importance of activation of EGFR and other ERBB family members as an adaptive response and resistance mechanism to KRAS inhibition across cancer types (30, 34, 63).”
BackgroundVertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496 · cited 1×
“…previously published cases of lung neuroendocrine tumor (patient 105; 14), melanoma, small cell lung cancer and spindle cell carcinoma (patients 10, 21 and 8; 19) to create a pan-cancer cohort of 132 patients with KRAS G12C mutation and displaying acquired resistance to adagrasib, sotorasib, or…”
BackgroundDiverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479 · cited 4×
“14, 18, 19).”
BackgroundInfluentialPan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity
Kinker, G. S., Greenwald, A. C., Tal, R., Orlova, Z., Cuoco, M. S., McFarland, J. M., Warren, A., Rodman, C., Roth, J. A., Bender, S. A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00726-6 · Cited by 445
Self-citationHwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01134-8 · Cited by 426 · cited 3×
“We additionally used a panel of PDAC transcriptional subtype signatures as well as multiple curated gene sets from the previously published work (44, 50, 52, 53, 88–91).”
MethodResultSelf-citationPapke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399
False Discovery Rates: A New DealPreprint
Stephens, M. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/038216 · Cited by 376
Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer
Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1066 · Cited by 370 · cited 3×
“Moreover, MRTX1133 has been shown to confer robust short-term responses in genetically engineered mouse models (GEMM) of PDAC (33) and displayed increased efficacy when combined with immune checkpoint blockade (32).”
BackgroundResultSelf-citationConcurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Holderfield, M., Lee, B. J., Jiang, J., Tomlinson, A., Seamon, K. J., Mira, A., Patrucco, E., Goodhart, G., Dilly, J., Gindin, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07205-6 · Cited by 369
Self-citationYu, C., Mannan, A. M., Yvone, G. M., Ross, K. N., Zhang, Y.-L., Marton, M. A., Taylor, B. R., Crenshaw, A., Gould, J. Z., Tamayo, P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3460 · Cited by 362 · cited 1×
“42, 43).”
GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer
O’Kane, G. M., Grünwald, B. T., Jang, G.-H., Masoomian, M., Picardo, S., Grant, R. C., Denroche, R. E., Zhang, A., Wang, Y., Miller, J. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3724 · Cited by 352 · cited 1×
“Patient data suggest that the classical subtype of PDAC responds better to chemotherapy than the poorly prognostic basal-like PDAC subtype (44, 58, 59).”
BackgroundTranslational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
Self-citationWang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., Mirakhur, B., & Chen, L.-T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.007 · Cited by 342 · cited 1×
“…be confirmed in larger studies, the efficacy of sotorasib and adagrasib in advanced, chemother-apy-treated disease compares favorably to historical data on second-line chemotherapy efficacy in PDAC, where response rates are consistently less than 10% and median PFS is less than 3 months (28, 29).”
ResultSingle-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303810 · Cited by 328 · cited 8×
“At the genomic level, we did not observe putative drug-binding site mutations in Kras , such as those that have previously been noted to cause resistance to KRAS inhibition in human tumors (14, 18, 20).”
BackgroundMethodResultInfluentialAdagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation
Bekaii-Saab, T. S., Yaeger, R., Spira, A. I., Pelster, M. S., Sabari, J. K., Hafez, N., Barve, M., Velastegui, K., Yan, X., Shetty, A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00434 · Cited by 313 · cited 1×
“In this cohort, an ORR of 33.3%, a PFS of 5.4 months, and an OS of 8.0 months were observed (27).”
BackgroundInfluentialSelf-citationBurke, J. E., Perisic, O., Masson, G. R., Vadas, O., & Williams, R. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205508109 · Cited by 300 · cited 1×
“The second most resistant PDO to MRTX1133 (PF0069_T1) harbors a PIK3CA G118D mutation, a known oncogenic alteration leading to enhanced PIK3CA activity and signaling (46, 47).”
BackgroundChemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors
De Raedt, T., Walton, Z., Yecies, J. L., Li, D., Chen, Y., Malone, C. F., Maertens, O., Jeong, S. M., Bronson, R. T., Lebleu, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.014 · Cited by 258 · cited 1×
“S8D), several of which have been previously associated with resistance to KRAS pathway suppression or inhibition (5, 55).”
BackgroundMahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Moreno Diaz, B. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.002 · Cited by 258
Self-citationTumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., et al. (2024) · Nature · doi:10.1038/s41586-024-07379-z · Cited by 209 · cited 1×
“Recently developed “pan-RAS” or “pan-KRAS” inhibitors capable of targeting all RAS isoforms or all KRAS alleles will be broadly applicable to most patients with PDAC (71–74).”
BackgroundSelf-citationGermline PIK3CA and AKT1 mutations in cowden and cowden-like syndromes
Orloff, M. S., He, X., Peterson, C., Chen, F., Chen, J.-L., Mester, J. L., & Eng, C. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.10.021 · Cited by 201 · cited 1×
“The second most resistant PDO to MRTX1133 (PF0069_T1) harbors a PIK3CA G118D mutation, a known oncogenic alteration leading to enhanced PIK3CA activity and signaling (46, 47).”
BackgroundLee, J. K., Sivakumar, S., Schrock, A. B., Madison, R., Fabrizio, D., Gjoerup, O., Ross, J. S., Frampton, G. M., Napalkov, P., Montesion, M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00334-z · Cited by 187 · cited 2×
“KRAS G12D mutations occur in nearly 40% of PDAC (25) and the recent development of selective inhibitors of the KRAS G12D mutant protein may have substantial clinical impact on the treatment of patients with PDAC (30, 31).”
BackgroundPharmacological targeting of netrin-1 inhibits EMT in cancer
Lengrand, J., Pastushenko, I., Vanuytven, S., Song, Y., Venet, D., Sarate, R. M., Bellina, M., Moers, V., Boinet, A., Sifrim, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06372-2 · Cited by 168 · cited 1×
“Exploring the therapeutic implications of emerging surface targets associated with the EMT phenotype, including Netrin-1 (67, 68) and CD70 (69), may prove promising in combination with KRAS inhibition.”
BackgroundNetrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer
Cassier, P. A., Navaridas, R., Bellina, M., Rama, N., Ducarouge, B., Hernandez-Vargas, H., Delord, J.-P., Lengrand, J., Paradisi, A., Fattet, L., et al. (2023) · Nature · doi:10.1038/s41586-023-06367-z · Cited by 161 · cited 1×
“Exploring the therapeutic implications of emerging surface targets associated with the EMT phenotype, including Netrin-1 (67, 68) and CD70 (69), may prove promising in combination with KRAS inhibition.”
BackgroundKEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160 · cited 1×
“45).”
Self-citationTumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154 · cited 1×
“…including the adoption of a KRAS-independent cell state dependent on oxidative phosphorylation (5), induction of SMARCB–MYC-network-driven mesenchymal reprogramming (38), activation of the TGF β - SMAD3/4 axis via TME remodeling (39), and USP21-mediated upregulation of macropinocytosis (40).”
BackgroundWeiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0158 · Cited by 150 · cited 1×
“…have shown promising efficacy in advanced, previously treated non–small cell lung cancer (NSCLC), leading to United States Food and Drug Administration (FDA) accelerated approval of two of these therapies (adagrasib and sotorasib) and many others being investigated in this setting (9–17).”
BackgroundMugarza, E., van Maldegem, F., Boumelha, J., Moore, C., Rana, S., Llorian Sopena, M., East, P., Ambler, R., Anastasiou, P., Romero-Clavijo, P., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm8780 · Cited by 142
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer
Tong, X., Patel, A. S., Kim, E., Li, H., Chen, Y., Li, S., Liu, S., Dilly, J., Kapner, K. S., Zhang, N., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.012 · Cited by 142
Self-citationCarugo, A., Genovese, G., Seth, S., Nezi, L., Rose, J. L., Bossi, D., Cicalese, A., Shah, P. K., Viale, A., Pettazzoni, P. F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.063 · Cited by 141 · cited 2×
“Mice experiments using PDXs were derived as previously described (84).”
MethodSelf-citationJänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31076-5 · Cited by 140 · cited 2×
“…alterations at the time of acquired resistance were observed in several patients, including amplifications/gains of KRAS G12C (patients 6, 9, 13, 22), amplification/ gain of EGFR (patients 2, 13), activating PIK3CA mutations (patients 13, 22), and an oncogenic NFE2L2 D29H variant (patient 21; Fig.”
BackgroundSelf-citationSynthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017) · Nature · doi:10.1038/nature21064 · Cited by 131 · cited 2×
“…of KRAS via RNA interference or genetically engineered inducible Kras G12D alleles (i.e., “ iKras ” model) have suggested that amplification of YAP1 or induction of an epithelial-to-mesenchymal transition (EMT) can confer a state of RAS independence and overcome KRAS G12D suppression (35–38).”
BackgroundSelf-citationWilliams, H. L., Costa, A. D., Zhang, J., Raghavan, S., Winter, P. S., Kapner, K. S., Ginebaugh, S. P., Väyrynen, S. A., Väyrynen, J. P., Yuan, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-3050 · Cited by 119 · cited 1×
“2), nuclear marker (DAPI), and epithelial cell marker (pan-cytokeratin) was developed following previously described methodology (86).”
MethodSelf-citationCD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
Nilsson, M. B., Yang, Y., Heeke, S., Patel, S. A., Poteete, A., Udagawa, H., Elamin, Y. Y., Moran, C. A., Kashima, Y., Arumugam, T., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.007 · Cited by 106 · cited 1×
“Exploring the therapeutic implications of emerging surface targets associated with the EMT phenotype, including Netrin-1 (67, 68) and CD70 (69), may prove promising in combination with KRAS inhibition.”
BackgroundSelf-citationRapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y. S., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K. L., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155523 · Cited by 103 · cited 1×
“…mechanisms of acquired resistance in patients with lung and colorectal cancer (CRC) treated with KRAS G12C inhibitors, including mutations in KRAS or other RTK–RAS–MAPK pathway effectors, adaptive signaling alterations, and histologic transformation to drug-resistant cell states (14, 18–24).”
BackgroundDual inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma
Gulay, K. C. M., Zhang, X., Pantazopoulou, V., Patel, J., Esparza, E., Pran Babu, D. S., Ogawa, S., Weitz, J., Ng, I., Mose, E. S., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1313 · Cited by 89 · cited 2×
“Additional investigations of combination therapy strategies with MRTX1133 in preclinical models of PDAC have suggested that co-targeting of EGFR may have enhanced efficacy over monotherapy (30, 34).”
BackgroundRapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
Tsai, Y., Woodcock, M. G., Azam, S. H., Thorne, L. B., Kanchi, K., Parker, J. S., Vincent, B. G., & Pecot, C. V. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 87
Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications
Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132319 · Cited by 78 · cited 1×
“2-targeting therapies have demonstrated efficacy in clinical trials for GI cancers, including antibodies, antibody-drug conjugates (ADC), and CAR-T cells (64–66).”
BackgroundRiely, G. J., Ou, S.-H. I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J. K., Johnson, M., Heist, R. S., Bazhenova, L., Barve, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(21)01941-9 · Cited by 77
Self-citationGarcia, P. L., Miller, A. L., & Yoon, K. J. (2020) · Cancers · doi:10.3390/cancers12051327 · Cited by 77 · cited 1×
“Human patient-derived xenograft (PDX) models have been shown to faithfully recapitulate human PDAC subtype diversity, including both classical and basal-like subtypes (56), with the basal-like PDAC phenotype showing phenotypic similarities with the mesenchymal cell state in PDAC (57).”
BackgroundQiang, L., Hoffman, M. T., Ali, L. R., Castillo, J. I., Kageler, L., Temesgen, A., Lenehan, P., Wang, S. J., Bello, E., Cardot-Ruffino, V., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.038 · Cited by 75
Self-citationWang, K., Patkar, S., Lee, J. S., Gertz, E. M., Robinson, W., Schischlik, F., Crawford, D. R., Schäffer, A. A., & Ruppin, E. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0887 · Cited by 55
Pitter, K. L., Grbovic-Huezo, O., Joost, S., Singhal, A., Blum, M., Wu, K., Holm, M., Ferrena, A., Bhutkar, A. J., Hudson, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1742 · Cited by 40
USP21 deubiquitinase elevates macropinocytosis to enable oncogenic KRAS bypass in pancreatic cancer
Hou, P., Ma, X., Yang, Z., Zhang, Q., Wu, C.-J., Li, J., Tan, L., Yao, W., Yan, L., Zhou, X., et al. (2021) · Genes & Development · doi:10.1101/gad.348787.121 · Cited by 35 · cited 1×
“…including the adoption of a KRAS-independent cell state dependent on oxidative phosphorylation (5), induction of SMARCB–MYC-network-driven mesenchymal reprogramming (38), activation of the TGF β - SMAD3/4 axis via TME remodeling (39), and USP21-mediated upregulation of macropinocytosis (40).”
BackgroundCollection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting
Raymond, C. K., Hernandez, J., Karr, R. M., Hill, K., & Li, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176241 · Cited by 28 · cited 1×
“Pretreatment and EOT ctDNA samples from patients 1, 2, 3, 5, 6, 7, 23, 24, 25, and 26 treated with adagrasib were subjected to the RESOLUTION ctDx FIRST assay developed at Resolution Biosciences (76).”
MethodHuffman, B. M., Basu Mallick, A., Horick, N. K., Wang-Gillam, A., Hosein, P. J., Morse, M. A., Beg, M. S., Murphy, J. E., Mavroukakis, S., Zaki, A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.49720 · Cited by 25 · cited 1×
“…be confirmed in larger studies, the efficacy of sotorasib and adagrasib in advanced, chemother-apy-treated disease compares favorably to historical data on second-line chemotherapy efficacy in PDAC, where response rates are consistently less than 10% and median PFS is less than 3 months (28, 29).”
ResultSelf-citationBahrambeigi, V., Lee, J. J., Branchi, V., Rajapakshe, K., Xu, Z., Kui, N., Henry, J. T., Wang, K., Stephens, B. M., Dhebat, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-4070 · Cited by 23
Self-citation
Cited by
KRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Yang, X., & Wu, H. K. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01631-9 · Cited by 146
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 131
Spatial mapping of transcriptomic plasticity in metastatic pancreatic cancer
Pei, G., Min, J., Rajapakshe, K., Branchi, V., Liu, Y., Selvanesan, B. C., Thege, F. I., Sadeghian, D., Zhang, D., Cho, K. S., et al. (2025) · Nature · doi:10.1038/s41586-025-08927-x · Cited by 148
“5), along with CAFs previously established from patients with PDAC 16,25,26 .”
Self-citationConsensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 109
Self-citation
Metadata
- Authors
- Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., Uribe, G. A., Yang, A., Kapner, K. S., Hambitzer, F. P., Qiang, L., Feng, H., Geisberg, J., Wang, J., Evans, K. E., Lyu, H., Schalck, A., Feng, N., Lopez, A. M., Bristow, C. A., Kim, M. P., Rajapakshe, K. I., Bahrambeigi, V., Roth, J. A., Garg, K., Guerrero, P. A., Stanger, B. Z., Cristea, S., Lowe, S. W., Baslan, T., Van Allen, E. M., Mancias, J. D., Chan, E., Anderson, A., Katlinskaya, Y. V., Shalek, A. K., Hong, D. S., Pant, S., Hallin, J., Anderes, K., Olson, P., Heffernan, T. P., Chugh, S., Christensen, J. G., Maitra, A., Wolpin, B. M., Raghavan, S., Nowak, J. A., Winter, P. S., Dougan, S. K., & Aguirre, A. J.
- Affiliations
- Broad Institute (US)
- Harvard University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- 3Harvard Medical School, Boston, Massachusetts.
- 8Exact Sciences, Redwood City, California.
- University of Pennsylvania (US)
- Memorial Sloan Kettering Cancer Center (US)
- 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Amgen (United States) (US)
- Mirati Therapeutics (United States) (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Aguirre, Andrew J.
- ORCID
- Dilly, Julien
- Hoffman, Megan T.
- Abbassi, Laleh
- Li, Ziyue
- Paradiso, Francesca
- Parent, Brendan D.
- Hennessey, Connor J.
- Jordan, Alexander C.
- Morgado, Micaela
- Dasgupta, Shatavisha
- Uribe, Giselle A.
- Yang, Annan
- Kapner, Kevin S.
- Hambitzer, Felix P.
- Qiang, Li
- Feng, Hanrong
- Geisberg, Jacob
- Wang, Junning
- Evans, Kyle E.
- Lyu, Hengyu
- Schalck, Aislyn
- Feng, Ningping
- Lopez, Anastasia M.
- Bristow, Christopher A.
- Kim, Michael P.
- Rajapakshe, Kimal I.
- Bahrambeigi, Vahid
- Roth, Jennifer A.
- Garg, Kavita
- Guerrero, Paola A.
- Stanger, Ben Z.
- Cristea, Simona
- Lowe, Scott W.
- Baslan, Timour
- Van Allen, Eliezer M.
- Mancias, Joseph D.
- Chan, Emily
- Anderson, Abraham
- Katlinskaya, Yuliya V.
- Shalek, Alex K.
- Hong, David S.
- Pant, Shubham
- Hallin, Jill
- Anderes, Kenna
- Olson, Peter
- Heffernan, Timothy P.
- Chugh, Seema
- Christensen, James G.
- Maitra, Anirban
- Wolpin, Brian M.
- Raghavan, Srivatsan
- Nowak, Jonathan A.
- Winter, Peter S.
- Dougan, Stephanie K.
- Aguirre, Andrew J.
- Venue
- Cancer Discovery
- Published
- 2024-07-05
- Volume
- 14
- Issue
- 11
- Pages
- 2135-2161
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC11528210
- OpenAlex
- W4400416998
- Semantic Scholar
- 5523d24bee9ee8e296cf3c0bde017f0d9fee7408
- Cited by
- 308
- References
- 100
- Citations by year
- 2026: 162 · 2025: 129 · 2024: 17
- FWCI
- 54.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Break Through Cancer
- National Cancer Institute (R01 CA276268, U01 CA274276, P50CA127003, P50CA221707, R01CA218230)
- Hale Family Center for Pancreatic Cancer Research
- Lustgarten Foundation
- Pancreatic Cancer Action Network
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS inhibition, acquired drug resistance, pancreatic ductal adenocarcinoma, KRAS G12C, KRAS G12D, adagrasib, sotorasib, MRTX1133, PIK3CA mutation, PI3K/AKT/mTOR pathway, epithelial-mesenchymal transition, KPC mouse model, organoid models, combination therapy, chemotherapy, YAP, c-Myc, CDK6, non-genetic resistance, drug resistance mechanisms
- MeSH terms
- Animals, Humans, Mutation, Pancreatic Neoplasms, Pyrimidines, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.